BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

(2016) X. Niu et al.   CLINICAL CANCER RESEARCH

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise

(2016) Kristopher A. Sarosiek et al.   FEBS Journal

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs

(2015) M Hugle et al.   CELL DEATH AND DIFFERENTIATION

Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma

(2015) U Heinicke et al.   ONCOGENE

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

(2015) G S Choudhary et al.   Cell Death & Disease

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

(2015) D C Phillips et al.   Blood Cancer Journal

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis

(2015) Ulrike Heinicke et al.   Oncotarget

MCL-1 dependency of cisplatin-resistant cancer cells

(2014) Judith Michels et al.   BIOCHEMICAL PHARMACOLOGY

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

(2014) S. Peirs et al.   BLOOD

Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA

(2014) Ulrike Heinicke et al.   CANCER LETTERS

Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199

(2014) S L Khaw et al.   LEUKEMIA

Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma

(2013) Xiang Chen et al.   CANCER CELL

Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein

(2013) Ellen Preuss et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

(2013) Hernan Carol et al.   PEDIATRIC BLOOD & CANCER

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Targeting mitochondria for cancer therapy

(2010) Simone Fulda et al.   NATURE REVIEWS DRUG DISCOVERY

JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

(2009) J. Arts et al.   CLINICAL CANCER RESEARCH

Rhabdomyosarcoma in children

(2009) Andrea Hayes-Jordan et al.   CURRENT OPINION IN PEDIATRICS

Cooperative Trial CWS-91 for Localized Soft Tissue Sarcoma in Children, Adolescents, and Young Adults

(2009) Tobias M. Dantonello et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetics in cancer: Targeting chromatin modifications

(2009) L. Ellis et al.   MOLECULAR CANCER THERAPEUTICS

Histone deacetylase inhibitors cooperate with IFN-γ to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8

(2009) S Häcker et al.   ONCOGENE

Apoptosis: controlled demolition at the cellular level

(2007) Rebecca C. Taylor et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY